NO346835B1 - Anvendelse av anti-CS1 antistoffet HuLuc63 i kombinasjonsbehandlinger for behandling av multippelt myelom - Google Patents
Anvendelse av anti-CS1 antistoffet HuLuc63 i kombinasjonsbehandlinger for behandling av multippelt myelom Download PDFInfo
- Publication number
- NO346835B1 NO346835B1 NO20090968A NO20090968A NO346835B1 NO 346835 B1 NO346835 B1 NO 346835B1 NO 20090968 A NO20090968 A NO 20090968A NO 20090968 A NO20090968 A NO 20090968A NO 346835 B1 NO346835 B1 NO 346835B1
- Authority
- NO
- Norway
- Prior art keywords
- huluc63
- approx
- lenalidomide
- administration
- antibody
- Prior art date
Links
- 229960004137 elotuzumab Drugs 0.000 title claims description 117
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims description 39
- 238000011282 treatment Methods 0.000 title claims description 35
- 208000034578 Multiple myelomas Diseases 0.000 title claims description 21
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 87
- 229960004942 lenalidomide Drugs 0.000 claims description 51
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 229960003957 dexamethasone Drugs 0.000 claims description 19
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 238000001990 intravenous administration Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 description 69
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 61
- 229960001467 bortezomib Drugs 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 48
- 230000004044 response Effects 0.000 description 22
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 20
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 17
- 102100029198 SLAM family member 7 Human genes 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 201000000050 myeloid neoplasm Diseases 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 231100000682 maximum tolerated dose Toxicity 0.000 description 14
- 239000012636 effector Substances 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000009089 cytolysis Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229960004679 doxorubicin Drugs 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229960003433 thalidomide Drugs 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 230000001446 anti-myeloma Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960001924 melphalan Drugs 0.000 description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 4
- 210000004180 plasmocyte Anatomy 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 201000009295 smoldering myeloma Diseases 0.000 description 3
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229940099039 velcade Drugs 0.000 description 3
- 206010061728 Bone lesion Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 231100000026 common toxicity Toxicity 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100001156 grade 3 toxicity Toxicity 0.000 description 2
- 231100000226 haematotoxicity Toxicity 0.000 description 2
- 208000036796 hyperbilirubinemia Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020740 Hyperproteinaemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 102100032965 Myomesin-2 Human genes 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 102000015094 Paraproteins Human genes 0.000 description 1
- 108010064255 Paraproteins Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 230000007495 abnormal renal function Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 229940127079 antineoplastic immunimodulatory agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940065533 lenalidomide 15 mg Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83618506P | 2006-08-07 | 2006-08-07 | |
| US94426207P | 2007-06-15 | 2007-06-15 | |
| PCT/US2007/075403 WO2008019378A1 (en) | 2006-08-07 | 2007-08-07 | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20090968L NO20090968L (no) | 2009-04-30 |
| NO346835B1 true NO346835B1 (no) | 2023-01-23 |
Family
ID=38831279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090968A NO346835B1 (no) | 2006-08-07 | 2007-08-07 | Anvendelse av anti-CS1 antistoffet HuLuc63 i kombinasjonsbehandlinger for behandling av multippelt myelom |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US8632772B2 (OSRAM) |
| EP (5) | EP2068874B1 (OSRAM) |
| JP (1) | JP5340935B2 (OSRAM) |
| CN (1) | CN101686971B (OSRAM) |
| AU (1) | AU2007281684C1 (OSRAM) |
| BR (1) | BRPI0716647A2 (OSRAM) |
| CA (1) | CA2660356C (OSRAM) |
| CY (5) | CY1116247T1 (OSRAM) |
| DK (2) | DK2641601T3 (OSRAM) |
| ES (2) | ES2535437T3 (OSRAM) |
| HR (2) | HRP20150449T1 (OSRAM) |
| HU (4) | HUE029027T2 (OSRAM) |
| IL (2) | IL196919A (OSRAM) |
| LT (4) | LT2641601T (OSRAM) |
| LU (3) | LU93276I2 (OSRAM) |
| MX (1) | MX2009001441A (OSRAM) |
| NL (1) | NL300840I2 (OSRAM) |
| NO (1) | NO346835B1 (OSRAM) |
| NZ (1) | NZ574978A (OSRAM) |
| PL (2) | PL2641601T3 (OSRAM) |
| PT (2) | PT2641601T (OSRAM) |
| SI (2) | SI2068874T1 (OSRAM) |
| WO (1) | WO2008019378A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010500370A (ja) | 2006-08-07 | 2010-01-07 | ピーディーエル バイオファーマ，インコーポレイティド | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| HUE029027T2 (en) | 2006-08-07 | 2017-01-30 | Abbvie Biotherapeutics Inc | Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies |
| JP2011523560A (ja) | 2008-06-02 | 2011-08-18 | ダナ−ファーバー キャンサー インスティテュート インク． | Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド |
| NZ589880A (en) | 2008-06-16 | 2012-10-26 | Immunogen Inc | Use of synergistic anti-cancer compositions comprising lenalidomide, at least one corticosteroid and at least one immunoconjugate |
| PE20120059A1 (es) * | 2008-10-21 | 2012-02-27 | Onyx Therapeutics Inc | Combinaciones farmaceuticas con epoxicetonas peptidicas |
| EP2476438B1 (en) * | 2009-09-10 | 2014-07-23 | Kyowa Hakko Kirin Co., Ltd. | Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4) |
| CA2780998C (en) * | 2009-11-24 | 2016-07-12 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
| CN102241773B (zh) * | 2010-05-13 | 2014-05-14 | 四川大学 | 抗骨髓瘤细胞多克隆抗体及其制备方法 |
| CN105377288B (zh) | 2012-11-05 | 2019-11-15 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138和cs1肽的组合物制备药物的用途 |
| EP3066127A1 (en) | 2013-11-06 | 2016-09-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| WO2015069785A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| CA2924268C (en) * | 2013-11-21 | 2021-05-18 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
| LT3182996T (lt) * | 2014-08-22 | 2023-03-10 | Celgene Corporation | Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais |
| WO2016049022A1 (en) * | 2014-09-23 | 2016-03-31 | Board Of Trustees Of Michigan State University | Compositions and methods for modulating an immune response |
| WO2016054354A1 (en) | 2014-10-02 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
| WO2016070089A2 (en) | 2014-10-31 | 2016-05-06 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| US10302644B2 (en) | 2014-11-04 | 2019-05-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
| BR112017011538A2 (pt) * | 2014-12-04 | 2018-03-13 | Bristol-Myers Squibb Company | combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) |
| HRP20210552T1 (hr) | 2015-05-13 | 2021-05-14 | Morphosys Ag | Liječenje multiplog mijeloma (mm) |
| ES2886657T3 (es) * | 2015-06-29 | 2021-12-20 | Bristol Myers Squibb Co | Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer |
| CN109432398A (zh) * | 2016-03-13 | 2019-03-08 | 曹帅 | 一种用于治疗骨髓增生、骨癌的药物组合物及其用途 |
| SG11201907923VA (en) | 2017-03-29 | 2019-09-27 | Agency Science Tech & Res | Anti oligosaccharide antibody |
| JP2021504475A (ja) * | 2017-11-22 | 2021-02-15 | ヒルストリーム・バイオファーマ・インコーポレイテッド | ボルテゾミブを含むポリマーナノ粒子 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| KR20220092578A (ko) | 2019-11-05 | 2022-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | M-단백질 검정 및 이의 용도 |
| CN115368462A (zh) * | 2022-07-19 | 2022-11-22 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040029832A1 (en) * | 2002-05-17 | 2004-02-12 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US20060024296A1 (en) * | 2003-05-08 | 2006-02-02 | Protein Design Labs, Inc. | Therapeutic use of anti-CS1 antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112969A (en) | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| WO1996037208A1 (en) | 1995-05-25 | 1996-11-28 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| CA2752140A1 (en) * | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer |
| EP1824513A4 (en) * | 2004-11-04 | 2010-06-09 | Fibron Ltd | TREATMENT OF B-CELL TUMORS |
| JP2010500370A (ja) | 2006-08-07 | 2010-01-07 | ピーディーエル バイオファーマ，インコーポレイティド | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| HUE029027T2 (en) | 2006-08-07 | 2017-01-30 | Abbvie Biotherapeutics Inc | Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies |
| US20080095768A1 (en) | 2006-08-07 | 2008-04-24 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
-
2007
- 2007-08-07 HU HUE13168383A patent/HUE029027T2/en unknown
- 2007-08-07 BR BRPI0716647A patent/BRPI0716647A2/pt not_active Application Discontinuation
- 2007-08-07 ES ES07840746.7T patent/ES2535437T3/es active Active
- 2007-08-07 DK DK13168383.1T patent/DK2641601T3/en active
- 2007-08-07 HR HRP20150449TT patent/HRP20150449T1/hr unknown
- 2007-08-07 PT PT131683831T patent/PT2641601T/pt unknown
- 2007-08-07 PL PL13168383T patent/PL2641601T3/pl unknown
- 2007-08-07 EP EP07840746.7A patent/EP2068874B1/en active Active
- 2007-08-07 PT PT78407467T patent/PT2068874E/pt unknown
- 2007-08-07 PL PL07840746T patent/PL2068874T3/pl unknown
- 2007-08-07 NO NO20090968A patent/NO346835B1/no unknown
- 2007-08-07 EP EP16169025.0A patent/EP3115049A1/en not_active Withdrawn
- 2007-08-07 MX MX2009001441A patent/MX2009001441A/es active IP Right Grant
- 2007-08-07 SI SI200731641T patent/SI2068874T1/sl unknown
- 2007-08-07 CN CN200780033988XA patent/CN101686971B/zh active Active
- 2007-08-07 AU AU2007281684A patent/AU2007281684C1/en active Active
- 2007-08-07 WO PCT/US2007/075403 patent/WO2008019378A1/en not_active Ceased
- 2007-08-07 EP EP13168383.1A patent/EP2641601B8/en active Active
- 2007-08-07 EP EP13168364.1A patent/EP2641600A1/en not_active Withdrawn
- 2007-08-07 NZ NZ574978A patent/NZ574978A/xx unknown
- 2007-08-07 CA CA2660356A patent/CA2660356C/en active Active
- 2007-08-07 EP EP15152731.4A patent/EP2942057A1/en not_active Withdrawn
- 2007-08-07 US US11/835,257 patent/US8632772B2/en active Active
- 2007-08-07 ES ES13168383.1T patent/ES2589302T3/es active Active
- 2007-08-07 SI SI200731803A patent/SI2641601T1/sl unknown
- 2007-08-07 DK DK07840746T patent/DK2068874T3/da active
- 2007-08-07 JP JP2009523968A patent/JP5340935B2/ja active Active
- 2007-08-07 LT LTEP13168383.1T patent/LT2641601T/lt unknown
-
2009
- 2009-02-05 IL IL196919A patent/IL196919A/en active Protection Beyond IP Right Term
-
2013
- 2013-12-23 US US14/139,096 patent/US20140322201A1/en not_active Abandoned
-
2015
- 2015-04-24 CY CY20151100379T patent/CY1116247T1/el unknown
- 2015-08-24 US US14/834,077 patent/US20160137735A1/en not_active Abandoned
-
2016
- 2016-02-03 IL IL243933A patent/IL243933A0/en unknown
- 2016-08-18 CY CY20161100817T patent/CY1117992T1/el unknown
- 2016-10-06 HR HRP20161284TT patent/HRP20161284T1/hr unknown
- 2016-10-20 HU HUS1600045C patent/HUS1600045I1/hu unknown
- 2016-10-20 HU HUS1600044C patent/HUS1600044I1/hu unknown
- 2016-10-20 HU HUS1600043C patent/HUS1600043I1/hu unknown
- 2016-10-24 LU LU93276C patent/LU93276I2/fr unknown
- 2016-10-24 LU LU93277C patent/LU93277I2/fr unknown
- 2016-10-24 LU LU93275C patent/LU93275I2/fr unknown
- 2016-10-25 NL NL300840C patent/NL300840I2/nl unknown
- 2016-10-26 CY CY2016038C patent/CY2016038I1/el unknown
- 2016-10-26 CY CY2016037C patent/CY2016037I1/el unknown
- 2016-10-26 CY CY2016036C patent/CY2016036I2/el unknown
- 2016-10-27 LT LTPA2016031C patent/LTC2068874I2/lt unknown
- 2016-10-27 LT LTPA2016029C patent/LTPA2016029I1/lt unknown
- 2016-10-27 LT LTPA2016030C patent/LTPA2016030I1/lt unknown
-
2017
- 2017-08-07 US US15/670,681 patent/US20170342150A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040029832A1 (en) * | 2002-05-17 | 2004-02-12 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| US20050025763A1 (en) * | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US20060024296A1 (en) * | 2003-05-08 | 2006-02-02 | Protein Design Labs, Inc. | Therapeutic use of anti-CS1 antibodies |
Non-Patent Citations (1)
| Title |
|---|
| KUMAR et al. Thalidomide and lenalidomide in the treatment of multiple myeloma. European Journal of Cancer. 2006, vol 42, s. 1612-1622. , Dated: 01.01.0001 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2660356C (en) | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies | |
| AU2007281682B2 (en) | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma | |
| US20080095768A1 (en) | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells | |
| HK1233169A (en) | Combination therapies based on anti-cs1 antibodies for treating multiple myeloma | |
| HK1233169A1 (en) | Combination therapies based on anti-cs1 antibodies for treating multiple myeloma | |
| HK1189515B (en) | Methods of treating multiple myeloma using combination therapies based on huluc63 with bortezomib | |
| HK1129853B (en) | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies | |
| HK1189515A (en) | Methods of treating multiple myeloma using combination therapies based on huluc63 with bortezomib | |
| HK1189516A (en) | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies | |
| HK1168759A (en) | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma | |
| HK1129849B (en) | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: DANA FARBER CANCER INSTITUTE INC, US |